Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 3/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172027 | 0.89 | IRAK4 (0.70) | IRAK4MAP3K7ALK | |
| SCHEMBL10171321 | 0.87 | IRAK4 (0.59) | IRAK4JAK3BTKPDPK1PAK4 | |
| SCHEMBL10171505 | 0.81 | IRAK4 (0.68) | IRAK4MAP3K7 | |
| SCHEMBL10172034 | 0.80 | IRAK4 (0.73) | IRAK4MAP3K7 | |
| SCHEMBL10171455 | 0.79 | IRAK4 (0.64) | IRAK4MAP3K7METALK | |
| SCHEMBL10171985 | 0.77 | IRAK4 (0.63) | IRAK4MAP3K7 | |
| SCHEMBL12112329 | 0.77 | IRAK4 (0.65) | IRAK4MAP3K7METALK | |
| SCHEMBL352181 | 0.77 | ALK (0.40) | IRAK4MAP3K7METALKMTNR1B | |
| SCHEMBL10171263 | 0.76 | IRAK4 (0.48) | IRAK4JAK3BTKPDPK1PAK4 | |
| SCHEMBL14484000 | 0.76 | IRAK4 (0.61) | IRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885JAK3 12/4885BTK 1/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885JAK3 12/4885BTK 1/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | IRAK4 293/4885JAK3 12/4885BTK 1/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | IRAK4 239/4885JAK3 12/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.